Literature DB >> 32820349

Association of early-onset diabetes, prediabetes and early glycaemic recovery with the risk of all-cause and cardiovascular mortality.

Sung Min Kim1, Gyeongsil Lee2, Seulggie Choi1, Kyuwoong Kim1, Su-Min Jeong2, Joung Sik Son2, Jae-Moon Yun2, Sin Gon Kim3, Seung-Sik Hwang4, Seong Yong Park5, Yeon-Yong Kim5, Sang Min Park6,7.   

Abstract

AIMS/HYPOTHESIS: The increasing incidence of diabetes among young adults is a disease burden; however, the effects of early-onset diabetes, prediabetes and glycaemic recovery on CVD or mortality remain unclear. We aimed to investigate the association of these factors with 10 year all-cause mortality, CVD mortality and CVD incidence in Korean young adults.
METHODS: This large and longitudinal cohort study included data from the Korean National Health Insurance Service-National Health Information Database; 2,502,375 young adults aged 20-39 years without diabetes mellitus and CVD at baseline were included. Glycaemic status was measured twice, first in 2002-2003 and second in 2004-2005. Changes in fasting glucose levels were evaluated according to fasting glucose status: normal fasting glucose (NFG; <5.5 mmol/l), impaired fasting glucose (IFG; 5.5-6.9 mmol/l), and diabetic fasting glucose (DFG; ≥7.0 mmol/l). Primary outcomes were all-cause and CVD mortality risk. The secondary outcome was incidence of CVD, including acute myocardial infarction and stroke. All outcomes arose from the 10 year follow-up period 1 Jan 2006 to 31 December 2015.
RESULTS: Individuals with NFG at baseline, who were subsequently newly diagnosed with diabetes and prediabetes (IFG), had increased all-cause mortality (HR [95% CI] 1.60 [1.44, 1.78] and 1.13 [1.09, 1.18], respectively) and CVD incidence (1.13 [1.05, 1.23] and 1.04 [1.01, 1.07], respectively). In those with DFG at baseline, early recovery to NFG and IFG was associated with decreased all-cause mortality (0.57 [0.46, 0.70] and 0.65 [0.53, 0.81], respectively) and CVD incidence (0.70 [0.60, 0.81] and 0.78 [0.66, 0.91], respectively). Among patients with IFG at baseline, early recovery to NFG was associated with decreased CVD mortality (0.74 [0.59, 0.93]). CONCLUSIONS/
INTERPRETATION: Early-onset diabetes or prediabetes increased CVD risks and all-cause mortality after the 10 year follow-up. Furthermore, recovery of hyperglycaemia could reduce the subsequent 10 year risk for CVD incidence and all-cause mortality. Graphical abstract.

Entities:  

Keywords:  All-cause mortality; Cardiovascular disease; Diabetes; Glycaemic recovery; Prediabetes

Year:  2020        PMID: 32820349     DOI: 10.1007/s00125-020-05252-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  3 in total

1.  Adding Estimated Cardiorespiratory Fitness to the Framingham Risk Score and Mortality Risk in a Korean Population-Based Cohort Study.

Authors:  Inhwan Lee; Jeonghyeon Kim; Hyunsik Kang
Journal:  Int J Environ Res Public Health       Date:  2022-01-03       Impact factor: 3.390

2.  Association Between Age at Diagnosis of Type 2 Diabetes and Cardiovascular Diseases: A Nationwide, Population-Based, Cohort Study.

Authors:  Chunyan Hu; Lin Lin; Yujing Zhu; Yi Zhang; Shuangyuan Wang; Jie Zhang; Hongyan Qi; Mian Li; Yuanyue Zhu; Yanan Huo; Qin Wan; Yingfen Qin; Ruying Hu; Lixin Shi; Qing Su; Xuefeng Yu; Li Yan; Guijun Qin; Xulei Tang; Gang Chen; Min Xu; Yu Xu; Tiange Wang; Zhiyun Zhao; Zhengnan Gao; Guixia Wang; Feixia Shen; Zuojie Luo; Li Chen; Qiang Li; Zhen Ye; Yinfei Zhang; Chao Liu; Youmin Wang; Tao Yang; Huacong Deng; Lulu Chen; Tianshu Zeng; Donghui Li; Jiajun Zhao; Yiming Mu; Yufang Bi; Weiqing Wang; Guang Ning; Shengli Wu; Yuhong Chen; Jieli Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-04       Impact factor: 5.555

3.  Interpretable disease prediction using heterogeneous patient records with self-attentive fusion encoder.

Authors:  Heeyoung Kwak; Jooyoung Chang; Byeongjin Choe; Sangmin Park; Kyomin Jung
Journal:  J Am Med Inform Assoc       Date:  2021-09-18       Impact factor: 7.942

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.